Things worth knowing about "Bone resorption"
Bone resorption is the process by which bone tissue is broken down by specialized cells. It is a natural part of bone metabolism but can lead to bone loss if it exceeds bone formation.
What is Bone Resorption?
Bone resorption is a biological process in which bone tissue is actively broken down and the minerals it contains – primarily calcium and phosphate – are released into the bloodstream. This process is a fundamental part of normal bone metabolism, also called bone remodeling, in which old bone tissue is continuously replaced by new bone. In a healthy body, bone resorption and bone formation remain in a carefully regulated balance.
How Does Bone Resorption Work?
The cells responsible for bone resorption are called osteoclasts. These large, multinucleated cells attach to the bone surface and secrete acids and enzymes that dissolve the bone matrix, releasing collagen fragments and minerals into circulation.
The opposing process – bone formation – is carried out by osteoblasts. The interplay between osteoclasts and osteoblasts is regulated by various hormones and signaling molecules, including:
- Parathyroid hormone (PTH): stimulates bone resorption to raise blood calcium levels
- Calcitonin: inhibits osteoclasts and reduces resorption
- Estrogen: protects bone by suppressing osteoclast activity
- Vitamin D: regulates calcium and phosphate metabolism
- RANKL/OPG system: central signaling pathway controlling osteoclast development and activity
Causes of Increased Bone Resorption
When bone resorption outpaces bone formation over time, bone mass and structural integrity are lost. Various factors can trigger this imbalance:
- Estrogen deficiency (e.g., after menopause): the most common cause of postmenopausal osteoporosis
- Hyperparathyroidism: overactive parathyroid glands producing excess PTH
- Vitamin D deficiency: impairs calcium absorption and promotes secondary hyperparathyroidism
- Physical inactivity: lack of mechanical loading weakens bone
- Chronic inflammatory diseases (e.g., rheumatoid arthritis, Crohn's disease)
- Long-term corticosteroid use
- Bone metastases: tumor cells in bone activate osteoclasts
- Paget's disease of bone: disordered bone remodeling with excessive resorption and formation
Consequences and Related Conditions
Persistent dominance of bone resorption over formation leads to a progressive loss of bone mass and density, increasing the risk of the following conditions:
- Osteoporosis: reduced bone density with elevated fracture risk
- Osteomalacia: softening of bone due to impaired mineralization
- Hypercalcemia: elevated blood calcium levels due to excessive release from bone
- Pathological fractures: bone fractures occurring without adequate trauma
Diagnosis
Several diagnostic tools are used to assess bone resorption and bone health:
- Bone density scan (DXA / dual-energy X-ray absorptiometry): gold standard for detecting bone loss
- Bone resorption markers in blood and urine: e.g., beta-CrossLaps (CTX), deoxypyridinoline – breakdown products of bone matrix collagen
- Blood tests: calcium, phosphate, parathyroid hormone, vitamin D, alkaline phosphatase
- X-ray and MRI: to evaluate bone structure and detect fractures
Treatment and Prevention
Treatment of excessive bone resorption targets the underlying cause. Common approaches include:
Pharmacological Treatment
- Bisphosphonates (e.g., alendronate, zoledronic acid): inhibit osteoclast activity and slow bone loss
- Denosumab: monoclonal antibody targeting RANKL, reducing osteoclast formation
- Selective estrogen receptor modulators (SERMs): e.g., raloxifene
- Hormone replacement therapy (HRT): for postmenopausal osteoporosis
- Teriparatide: anabolic parathyroid hormone analogue that stimulates bone formation
Nutrition and Lifestyle
- Adequate intake of calcium (approx. 1000–1200 mg/day per WHO/national guidelines) and vitamin D
- Regular weight-bearing physical activity, including strength training and aerobic exercise
- Avoiding smoking and excessive alcohol consumption
- Fall prevention strategies to reduce fracture risk
References
- World Health Organization (WHO): Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva, 1994.
- Rachner TD, Khosla S, Hofbauer LC: Osteoporosis: now and the future. The Lancet, 2011; 377(9773): 1276–1287.
- Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature, 2003; 423(6937): 337–342.